

# Dashboard

Dashboard is a feature that allows you to create customizable cards to present specific findings in Synthesis alongside our auto-generated outputs: Qualitative Synthesis, Quantitative Synthesis, Critical Appraisal, PRISMA 2009 & 2020 etc. These cards update as new data is inputted into the nest and are also easy to download for external use.

## Toggle Dashboard on in Settings

In any nest, by default, Dashboard is not enabled. To enable the Dashboard feature, head to Settings and toggle on under Synthesis:

### Synthesis

Synthesis outputs are generated in part by the actions taken in AutoLit. Turning on these outputs will allow you to visualize and share tags and gathered data.

#### Choose which outputs to display:

☒ Qualitative Synthesis

☒ Quantitative Synthesis

☒ Manuscript

☒ Dashboard

☒ Critical Appraisal

☒ PRISMA Diagram

After toggling Dashboard on, “Dashboard Editor” will be displayed underneath the Synthesis menu item:

Nest Home

Activity

Settings

Literature Search

Other Sources

Duplicate Review

Search Exploration

Abstract Screening

Adjudicate Screening

Full Text Screening

Adjudicate Screening

Tagging

Study Inspector

Synthesis

Dashboard Editor

Abstract Editor

Export

### Synthesis

Synthesis outputs are generated in part by the actions taken in AutoLit. Turning on these outputs will allow you to visualize and share tags and gathered data.

### Nest Access

Making this nest public will allow anyone on the internet to search for and see your nest's Synthesis. This does not grant the public editing access via AutoLit.

Making this nest protected will add a secret key to its Synthesis URLs, making them undiscoverable and inaccessible to those without the key (or explicitly granted access). You will still be able to share a link with external parties, and the external party will not have to log in to view Synthesis.

Making this nest private is the most secure option. Only users with explicitly granted access (either as an individual user or through their organization) will be able to view Synthesis.

#### Choose which outputs to display:

☒ Qualitative Synthesis

☐ Quantitative Synthesis

☐ Manuscript

☒ Dashboard

☐ Critical Appraisal

☒ PRISMA Diagram

#### Nest Access:

☐ Public

☒ Protected

☐ Private

Expire & Regenerate Key

#### Current Link to Synthesis:

https://nested-knowledge.com/nest/4691

Note: When you toggle on Dashboard, Manuscript Editor is automatically toggled off, but don't worry--no work is lost when you switch between features.

## Using Dashboard Editor

Navigate to Dashboard editor, and click the “+” icon in the top right to start adding cards by selecting

your desired option.

Nest Home

Activity

Settings

Literature Search

Other Sources

Duplicate Review

Search Exploration

Abstract Screening

Adjudicate Screening

Full Text Screening

Adjudicate Screening

Tagging

Study Inspector

Synthesis

Dashboard Editor

Abstract Editor

Export

Start adding cards to your dashboard by clicking '+' on the right!

Text

Table

PRISMA

Image






Study

## Dashboard Card Types

The card options are listed for you to choose from; we currently offer the following card types:

- **Text Card** = allows customized text input; the text editor offers the same tools as Abstract & Manuscript Editors

Research Question

H B I U S     

This nest focused on the following research questions:

- How did the general adult population fare in the short-term after COVID-19 diagnosis?
- How did the pediatric population fare after COVID-19 diagnosis?
- How do adult vs pediatric populations compare in terms of COVID-19 recovery?

Cancel

Add

Once added, the text card will be displayed as a card on the Dashboard:

Nest Home  
Activity  
Settings

Literature Search  
Other Sources  
Duplicate Review  
Search Exploration

Abstract Screening ⚙️  
Adjudicate Screening

Full Text Screening  
Adjudicate Screening

Tagging ⚙️

Study Inspector

Synthesis  
Dashboard Editor  
Abstract Editor  
Export

Research Question

This nest focused on the following research questions:

- How did the general adult population fare in the short-term after COVID-19 diagnosis?
- How did the pediatric population fare after COVID-19 diagnosis?
- How do adult vs pediatric populations compare in terms of COVID-19 recovery?

- **Table Card** = allows addition of an updateable custom table; the table offers the same tools as Custom Tables in Export, but includes a title and description to be displayed alongside other cards in Dashboard. Learn more about how to use custom tables [here](#).

Example Title

Example Description

Table of:

Study

Filter to:

Add

Columns:

Add

Column

Title

Column

Year

Column

Efficacy Outcomes

Previewing 1 of 1 rows

Title	Year	Efficacy Outcomes
Rilzabrutinib for the Treatment of C...	2021	[see text]

Cancel

Save

Once added, the table card will be displayed alongside existing cards on the Dashboard:

Nest Home

Activity

Settings

Literature Search

Other Sources

Duplicate Review

Search Exploration

Abstract Screening

Adjudicate Screening

Full Text Screening

Adjudicate Screening

Tagging

Study Inspector

Synthesis

Dashboard Editor

Abstract Editor

Export

Research Question

This nest focused on the following research questions:

- How did the general adult population fare in the short-term after COVID-19 diagnosis?
- How did the pediatric population fare after COVID-19 diagnosis?
- How do adult vs pediatric populations compare in terms of COVID-19 recovery?

Example Title

Title	Year	Efficacy Outcomes
Rilzabrutinib f...	2021	[see text]

- PRISMA Card** = allows addition of an updateable PRISMA diagram (either PRISMA 2009 or 2020); the diagram is the same as displayed in the Synthesis -> PRISMA tab, but includes a title and description to be displayed alongside other cards in Dashboard

PRISMA 2020

Description

Standard

20092020

Cancel

Add

Once added:

Nest Home

Activity

Settings

Literature Search

Other Sources

Duplicate Review

Search Exploration

Abstract Screening

Adjudicate Screening

Full Text Screening

Adjudicate Screening

Tagging

Study Inspector

Synthesis

Dashboard Editor

Abstract Editor

Export

Research Question

This nest focused on the following research questions:

- How did the general adult population fare in the short-term after COVID-19 diagnosis?
- How did the pediatric population fare after COVID-19 diagnosis?
- How do adult vs pediatric populations compare in terms of COVID-19 recovery?

Example Title

Title	Year	Efficacy Outcomes
Rilzabrutinib f...	2021	[see text]

PRISMA 2020

Identification of new studies via databases and registries

Records identified from:  
ClinicalTrials.gov (n=53)  
PubMed (n=7)

Records removed prior to screening:  
Duplicate records removed (n=0)  
Records still awaiting screening (n=48)

Records Screened (n=12)

Records excluded (n=10)  
Duplicate (n=10)

Reports sought for retrieval (n=2)

Reports not retrieved (n=0)

Reports assessed for eligibility (n=2)

Reports excluded (n=1)  
Duplicate (n=1)

Studies included in review (n=1)  
Reports of new included studies (n=1)

Identification of new studies via other methods

Records identified via:  
Expert Recommendation (n=1)

Reports sought for retrieval (n=0)

Reports not retrieved (n=0)

Reports assessed for eligibility (n=0)

Reports excluded (n=0)

- **Image Card** = allows addition of an image, including a title and description

Nested Knowledge Logo

Description

Upload Image (10Mb limit)

File uploaded!

Cancel

Add

Once added:

**Research Question**

This nest focused on the following research questions:

- How did the general adult population fare in the short-term after COVID-19 diagnosis?
- How did the pediatric population fare after COVID-19 diagnosis?
- How do adult vs pediatric populations compare in terms of COVID-19 recovery?

**Example Title**

Title	Year	Efficacy Outcomes
Rilzabrutinib f...	2021	[see text]

**PRISMA 2020**

Identification of new studies via databases and registries

Records identified from: ClinicalTrials.gov (n=53), PubMed (n=7)

Records removed prior to screening: Duplicate records removed (n=0), Records still awaiting screening (n=48)

Records Screened (n=12)

Records excluded (n=10): Duplicate (n=10)

Reports sought for retrieval (n=2)

Reports not retrieved (n=0)

Reports assessed for eligibility (n=2)

Reports excluded (n=1): Duplicate (n=1)

Studies included in review (n=1): Reports of new included studies (n=1)

Identification of new studies via other methods

Records identified via: Expert Recommendation (n=1)

Reports sought for retrieval (n=0)

Reports not retrieved (n=0)

Reports assessed for eligibility (n=0)

Reports excluded (n=0)

**Nested Knowledge Logo**

{NESTED} KNOWLEDGE

- **Study Card** = allows you to spotlight a specific included study in the nest; search for a specific study using author name

**Study Highlight**

This study was particularly outstanding because...

sa

Sanofi 2021

Cancer

ADD

Once added, the abstract is displayed with RoboPICO highlighting and this particular card is entirely interactive. You can explore the data, tags, search origin, and even link out to the full text.

**Research Question**

This nest focused on the following research questions:

- How did the general adult population fare in the short-term after COVID-19 diagnosis?
- How did the pediatric population fare after COVID-19 diagnosis?
- How do adult vs pediatric populations compare in terms of COVID-19 recovery?

**Example Title**

Title	Year	Efficacy Outcomes
Rilzabrutinib f...	2021	[see text]

**PRISMA 2020**

Identification of new studies via databases and registries

Records identified from: ClinicalTrials.gov (n=53), PubMed (n=7)

Records removed prior to screening: Duplicate records removed (n=0), Records still awaiting screening (n=48)

Records Screened (n=12)

Records excluded (n=10): Duplicate (n=10)

Reports sought for retrieval (n=2)

Reports not retrieved (n=0)

Reports assessed for eligibility (n=2)

Reports excluded (n=1): Duplicate (n=1)

Studies included in review (n=1): Reports of new included studies (n=1)

Identification of new studies via other methods

Records identified via: Expert Recommendation (n=1)

Reports sought for retrieval (n=0)

Reports not retrieved (n=0)

Reports assessed for eligibility (n=0)

Reports excluded (n=0)

**Study Highlight**

**Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine (RILECSU)**

Sanofi

11/24/2021

Abstract Data Tags Searches Google Scholar

Brief Summary: The first phase of this study will be a parallel, 12-week treatment, Phase 2, double-blind, 4 arm study to assess the safety and effectiveness of 3 oral doses of SAR444671 (rilzabrutinib), i.e. dose A, B and C, compared with placebo for decreasing the frequency and severity of itch and urticaria in male and female participants aged 18 years inclusive or older with CSU. After completion of the double-blind phase of the study, participants will be given the option of enrolling in the 40-week open label extension (OLE) phase of the study. Participants will receive open-label rilzabrutinib at dose C (the dose may be modified based on the 12-week safety and efficacy data). Due to the fact that some participants may be receiving rilzabrutinib for the first time, all participants will be monitored at Week 14, Week 16, Week 20, and Week 24. Afterwards, participants will be monitored at Week 36 and Week 52. Detailed Description: Study Type: Interventional Actual Enrollment: 161 participants Status (as of import): Active, not recruiting

## Editing Dashboard Display

After mixing and matching your desired cards, you can adjust and move them as they are displayed in the editor and this will alter how they are displayed in Synthesis:

1. Drag and Drop cards by click anywhere within the card and moving their position
2. Expand or reduce the size of each card using the arrow in the bottom right corner, other cards will move accordingly

## Other Tools

1. Expand each card into an easy-to-view modal by clicking the arrows in the top left
2. View the card description by hovering over the “i” icon in the top right
3. Edit, download, or delete each card by using the pencil, download and “X” icons, respectively
  1. Text card exports as a word doc
  2. Table card exports as a .csv file
  3. Image and PRISMA cards export as a .jpg file

Note: the Download function is currently only available for Text, Table, Image, and PRISMA card types.

The screenshot displays the Synthesis Dashboard interface. On the left is a sidebar menu with options: Nest Home, Activity, Settings, Literature Search, Other Sources, Duplicate Review, Search Exploration, Abstract Screening, Adjudicate Screening, Full Text Screening, Adjudicate Screening, Tagging, Study Inspector, and Synthesis (with sub-options: Dashboard Editor, Abstract Editor, Export). The main area contains several cards: 'Research Question' with a list of COVID-19 related questions, 'Example Title' with a table of Rilzabrutinib data, 'Nested Knowledge Logo', 'PRISMA 2020' flow diagram, 'Example Text' (highlighted with a red box), and 'Study Highlight' for Rilececsu. A red box highlights the expand/collapse arrow in the top left of the PRISMA 2020 card. Another red box highlights the 'i' icon in the top right of the Example Text card. A third red box highlights the edit, download, and delete icons in the bottom left of the PRISMA 2020 card.

## Dashboard in Synthesis

To access Dashboard, head to Synthesis and click the “Dashboard” menu item. The appearance of Synthesis Dashboard will be exactly as configured in Dashboard Editor. Here you can expand each card (including resizability of columns within the table card), view associated descriptions, and download available cards.



Synthesis

Dashboard

Qualitative

Quantitative

Critical Appraisal

PRISMA

Back to AutoLit

Research Question

This nest focused on the following research questions:

- How did the general adult population fare in the short-term after COVID-19 diagnosis?
- How did the pediatric population fare after COVID-19 diagnosis?
- How do adult vs pediatric populations compare in terms of COVID-19 recovery?

Example Title

Title	Year	Efficacy Outcomes
Rilzabrutinib f...	2021	[see text]

Nested Knowledge Logo

{NESTED} KNOWLEDGE

PRISMA 2020

Identification of new studies via databases and registries

Records identified from:  
ClinicalTrials.gov (n=53)  
PubMed (n=7)

Records removed prior to screening:  
Duplicate records removed (n=0)  
Records still awaiting screening (n=5)

Records Screened (n=12)

Records excluded (n=10)  
Duplicate (n=10)

Records sought for retrieval (n=0)

Records not retrieved (n=0)

Records assessed for eligibility (n=0)

Records excluded (n=0)

Records included in review (n=1)  
Reports of new included studies (n=1)

Identification of new studies via other methods

Records identified via:  
Expert Recommendation (n=1)

Records removed prior to screening:  
Duplicate records removed (n=0)  
Records still awaiting screening (n=0)

Records Screened (n=1)

Records excluded (n=0)  
Duplicate (n=0)

Records sought for retrieval (n=0)

Records not retrieved (n=0)

Records assessed for eligibility (n=0)

Records excluded (n=0)

Records included in review (n=1)  
Reports of new included studies (n=1)

Study Highlight

Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine (RILECSU)

Sanofi

11/24/2021

Abstract Data Tags Searches

Google Scholar

Brief Summary: The first phase of this study will be a parallel, 12-week treatment, Phase 2, double-blind, 4 arm study to assess the **safety and effectiveness** of 3 oral doses of SAR444671 (rilzabrutinib), i.e. dose A, B and C, compared with placebo for decreasing the **frequency and severity of itch and urticaria** in male and female participants aged 18 years inclusive or older with CSU. After completion of the double-blind phase of the study, participants will be given the option of enrolling in the 40-week open label extension (OLE) phase of the study. Participants will receive open-label **rilzabrutinib** at dose C (the dose may be modified based on the 12-week safety and efficacy data). Due to the fact that some participants may be receiving **rilzabrutinib** for the first time, all participants will be monitored at Week 14, Week 16, Week 20, and Week 24. Afterwards, participants will be monitored at Week 36 and Week 52. Detailed Description: Study Type: **Interventional** Actual Enrollment: **161** participants Status (as of import): **Active, not recruiting**

Filtering Synthesis

While Synthesis Filters are unavailable for Dashboard & Manuscript, they can be applied to all other parts of Synthesis. Learn more about [Synthesis Filters](#).

Downloading Dashboard Cards

Any card that is downloadable will have the following icon when hovered over:

Synthesis

Dashboard

Qualitative

Quantitative

Critical Appraisal

PRISMA

Back to AutoLit

Dashboard: Dec 2023 Demo - AIS

Settings

more often than PC-LVO (40.7% [95% CI: 21.8–62.8%]) patients treated after 2014, but this effect was not observed prior to 2014.

Abstract Tags Data Searches

PubMed

BACKGROUND

Trials of **endovascular therapy** for ischemic stroke have produced variable results. We conducted this study to test whether more advanced imaging selection, recently developed devices, and earlier intervention improve outcomes. **METHODS** We randomly assigned patients with ischemic stroke who were receiving 0.9 mg of alteplase per kilogram of body weight less than 4.5 hours after the onset of ischemic stroke either to undergo endovascular thrombectomy with the Solitaire FR (Flow Restoration) stent retriever or to continue receiving alteplase alone. All the patients had occlusion of the internal carotid or middle cerebral artery and evidence of salvageable brain tissue and ischemic core of less than 70 ml on computed tomographic (CT) perfusion imaging. **The primary outcome was reperfusion at 24 hours and early neurological improvement.**

Table of Patient Characteristics

Title	First Author	Year	Patient Characteristics	DOI
Thrombectomy wit...	Jovin, Tudor G	2015	Parent Artery Loca...	10.1056/nejmoa15...
Clinical treatment ...	Zhao, Q-S	2018	Parent Artery Loca...	10.26355/eurev_2...
Endovascular ther...	Campbell, Bruce C V	2015	Parent Artery Loca...	10.1056/nejmoa14...
SWIFT DIRECT: S...	Fischer, Urs	2022	Age (Mean): Age, ...	10.1177/17474930...
A randomized trial ...	Berkhemer, Olivert A	2015	Parent Artery Loca...	10.1056/nejmoa14...
Aspiration thrombe...	Turk, Aquilla S	2019	Onset-to-groin pun...	10.1016/s0140-67...
Effect of Endovasc...	Zi, Wenjie	2021	Onset-to-groin pun...	10.1001/jama.202...
Stent-retriever thro...	Saver, Jeffrey L	2015	Onset-to-groin pun...	10.1056/nejmoa14...
Safety and efficacy...	Dávalos, Antoni	2017	Age (Mean): [Sele...	10.1016/s1474-44...
Endovascular thro...	Mitchell, Peter J	2022	Up to 4.5 hours: P...	10.1016/s0140-67...
Thrombectomy 6 t...	Nogueira, Raul G	2018	Onset-to-groin pun...	10.1056/nejmoa17...
Endovascular ther...	Muir, Keith W	2017	Internal carotid art...	10.1136/jnnp-2016...

PRISMA Chart

Identification of new studies via databases and registries

Records identified from:  
ClinicalTrials.gov (n=116)  
DOI (n=19)  
Embase (n=58)  
Europe PubMed Central (n=46)  
PubMed (n=515)

Records removed prior to screening:  
Duplicate records removed (n=13)  
Records still awaiting screening (n=236)

Records Screened (n=461)

Records excluded (n=440)

- Excluded: Biased subpopulation (n=1)
- Excluded: Does not relate to AIS (n=2)
- Excluded: Does not report patient outcomes (n=4)
- Excluded: Does not report use of mechanical thrombectomy (n=27)
- Excluded: Does not separate patient outcomes by AIS intervention (n=5)
- Excluded: Editorial (n=5)
- Excluded: Outcomes article (n=2)
- Excluded: In vitro study (n=2)
- Excluded: Mathematical model (n=1)
- Excluded: Meta-analysis or Systematic Review (n=17)
- Excluded: No Intervention of Interest (n=19)
- Excluded: No Outcome of Interest (n=1)
- Excluded: Not Published in English (n=3)
- Excluded: Not an RCT (n=45)
- Excluded: Not relevant to topic of interest (n=75)
- Excluded: Only randomized patients (n=1)
- Excluded: Opinion article (n=4)
- Excluded: Protocol or Methods article (n=1)
- Excluded: Published Before 2014-01-01 (n=4)
- Excluded: Retrospective Study (n=7)
- Excluded: Secondary analysis (n=12)
- Robot Excluded (n=1)

Reports sought for retrieval (n=21)

Reports not retrieved (n=0)

Reports assessed for eligibility (n=21)

Reports excluded (n=0)

Studies included in review (n=26)  
Reports of new included studies (n=27)

Identification of new studies via other methods

Records identified via:  
Bibliomining (n=21)  
Expert Recommendation (n=8)

Records removed prior to screening:  
Duplicate records removed (n=0)  
Records still awaiting screening (n=0)

Records Screened (n=29)

Records excluded (n=0)  
Duplicate (n=0)

Reports sought for retrieval (n=0)

Reports not retrieved (n=0)

Reports assessed for eligibility (n=0)

Reports excluded (n=0)

Studies included in review (n=26)  
Reports of new included studies (n=27)

Sharing Dashboard

Like other parts of Synthesis, and provided Synthesis is configured for public access (see Settings), Dashboard is available to share as a link or via QR code by click on the share icon in the top right corner, next to the ? wiki icon.

From:  
<https://wiki.nested-knowledge.com/> - **Nested Knowledge**

Permanent link:  
<https://wiki.nested-knowledge.com/doku.php?id=wiki:synthesis:dashboard&rev=1711988013>

Last update: **2024/04/01 16:13**